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The purpose of this evidenced-based project was to increase chlamydia pre-screening and 
screening in women under age 25 presenting with urinary symptoms. Interventions included 
chlamydia pre-screening alerts embedded into the electronic medical record. Three-month 
evaluation showed a chlamydia pre-screening rate of 100% and an increase in chlamydia 




















Chlamydia (CHL) is a wide spread sexually transmitted infection (STI) in San Diego county, 
California, and the nation. CHL is also one of the most commonly reported STIs in the United 
States. Females between the ages of 15 and 24 are at the highest risk for infection. Women with 
CHL are asymptomatic approximately half of the time, often causing women to seek treatment 
late when serious side effects are present.1 However, some women do have symptoms of CHL 
such as cervicitis, abnormal, thick vaginal discharge, bleeding and painful sex.1, 2 CHL can also 
cause typical symptoms of a urinary tract infection (UTI) such as dysuria. 3, 4 It is estimated 10 to 
50 % of women presenting with UTI symptoms in emergency care settings will have a STI such 
as CHL if tested.3   
CHL can also lead to pelvic inflammatory disease (PID), a serious upper genital tract 
infection in women. PID can result in infertility, chronic pelvic pain, and an increased risk of 
ectopic pregnancy. In 2012, there were approximately 750,000 cases of PID in the United States. 
Approximately 10 to 20 % of women with CHL or gonorrhea (GC), if left untreated, will 
develop PID. Although PID can frequently be treated in an outpatient setting, hospitalizations for 
PID have increased in the last 10 years adding to overall healthcare costs. The estimated cost in 
2012 for a patient with PID was 2,000 dollars, which translates into an annual cost of 1.5 billion 
dollars.2 In the US the annual costs for CHL in 2008 (calculated in 2010 U.S. dollars) were 516.7 
million. 5 Infertility associated with PID and CHL is approximately $ 6,000 per patient.6 
In the US in 2014, there were 1,441,789 reported cases of CHL. For the above reported cases 
69.8 % were women, for a case rate of 627.2 per 100,000 females.7 In 2013, the case rate for 
CHL was 439.9 per 100,000 people in the state of California. California also ranked 23rd among 
50 states in CHL infections. The CHL infection rate for California was two times greater in 
women than in men.8 San Diego County found there were 15,626 cases of CHL in 2013. Similar 
to California, San Diego County showed the rate of CHL in females was over twice the rate in 
males.9 Chlamydial infections are common and pose significant harm to the individual, 
community, state and nation. Therefore, it is important screening women for CHL especially in 
at risk populations.  
The SHC, where the project was implemented, collected data on CHL screening and 
compared it to the American College Health Association (ACHA) statistics. According to the 
ACHA benchmarking committee, 58% of the time the SHCs surveyed were compliant with the 
Centers for Disease Control and Prevention (CDC) CHL screening guidelines for women in 
spring of 2015.10 The project site screened for CHL in women per CDC guidelines 44% of the 
time.  
Synthesis of the Evidence 
The United States Preventive Service Task Force (USPSTF) recommends sexually active 
women under 25 have CHL screening.11 The Centers for Disease Control and Prevention (CDC) 
guidelines recommend annual CHL screening for sexually active women under 25.12 Two 
systematic reviews completed by the USPSTF (2007, 2014) confirm screening for CHL 
decreases the incidence of PID and improves health outcomes. 13-15 The most recent evidence for 
screening according to the USPSTF is Grade B evidence. Grade B evidence recommends 
providing a service because the net benefit moderately out weighs the net risk. The 
recommendation is a moderate level of certainty. This classification means the available 
evidence is sufficient enough to provide the preventative service. The USPSTF recommendation 
is classified this way instead of a high level of certainty because one randomize control trial 
reviewed by the USPSTF in the 2014 systematic review had mixed results on screening for 
CHL.11 The CDC guidelines are more specific than USPSTF because it recommends yearly CHL 
screening for sexually active women under 25. The CDC states although there may be higher 
incidences of CHL in women 25 and older in some communities, the overall burden of disease is 
in women younger than 25.12 The American Congress of Obstetricians and Gynecologist 
(ACOG) and American Academy of Pediatrics, recommend annual CHL screening in sexually 
active women 25 and under.15 
To increase CHL screening, one systematic review found 27 articles and a total of 30 
different programs.  These programs took place in educational settings. The researchers 
suggested screening provided during classroom based settings, annual physicals/health 
examinations at SHCs, as well as conducting opportunistic screening at SHCs screened the 
greatest number of patients. Across all the opportunistic screening programs at SHCs, 13,006 
CHL screenings were conducted. A detailed description of the type of opportunistic screening 
was not available from all of the programs, however some did state the types of interventions 
were advertisements around campuses, receptionist approaching patients with information about 
screening, and nurse/doctor offering screening after consultation.16 The screening intervention 
used in the EBP project is similar to providing opportunistic screening to patients after 
nurse/doctor consultation.  
Another systematic review in the primary care area analyzed 11 randomized control trials 
and five observational studies. The review determined six intervention strategies were helpful to 
increase CH screening.17 Two strategies from that review were included in this EBP project. The 
intervention strategies included computer alerts for providers in the electronic medical record 
(EMR) and education workshops for the clinic staff about the importance of CHL screening.  In 
the systematic review, the computer alerts increased screening from 10.6% to 12.2% and the 
education of staff increased screening from 12.4% to 15.5%.17  
Rationale 
The specific trigger to increase CHL screening rates in women presenting to the SHC was 
the lower CHL screening compliance rate compared to the ACHA’s findings. Staff also noted 
that many women who presented with urinary symptoms were not always screened for CHL. 
Additionally, there was no formal template in the electronic medical record (EMR) in dysuria 
visits to identify CHL screening. Pre-data, from 2015, at the project site indicated there were 320 
dysuria visits for women under age 25. About 6% of those dysuria visits had a CHL screening 
ordered. A total of 129 CHL screenings were ordered during 2015 but not necessarily during 
dysuria visits. Other visits that had a CHL screening ordered included vaginitis, annual physical, 
and encounter for STI screening.  There were also 3 positive CHL tests in 2015, however these 
positive tests were not associated with dysuria visits. The decreased CHL screening compliance 
rates at the project site compared to the ACHA’s findings, anecdotal and staff findings prompted 
the EBP project. The pre-data collected further supported the need for improvement in CHL 
screening during dysuria visits. Several interventions from the above systematic reviews were 
utilized in the project to increase CHL screening. 
Purpose 
The purpose of this EBP project was to increase CHL pre-screening and screening in 
women under age 25 who presented to the SHC with urinary symptoms over a 3-month period.  
Methods  
Definitions  
In order to increase CHL pre-screening and screening a multifaceted program was 
implemented. In the context of this EBP project, pre-screening was defined as the process of 
determining if a patient was indicated for CHL screening. Screening was defined as the actual 
CHL test ordered.  
Interventions 
The program implemented had six main components. First, an educational presentation 
was provided for all clinic staff to understand their role in the EBP project. The educational 
presentation also emphasized the importance of CHL screening in sexually active women under 
age 25. Second, an optional pre-visit questionnaire was generated for female patients presenting 
with urinary symptoms. This questionnaire was available online to female patients who booked 
an appointment through the online SHC portal. The questionnaire contained a pre-screening 
assessment template. This template had questions presented in an easy to understand format. 
After the patient finished the questionnaire the completed pre-screening assessment template was 
then embedded into EMR.  Third, if the patient did not use the questionnaire the pre-screening 
assessment template was inserted into the subjective section of the EMR encounter note for the 
provider to complete. The first question of the pre-screening assessment template asked about 
sexual activity. If the patient was sexually active, then the template continued with these three 
options; no prior STI screening, STI screening greater than 1 year or STI screening within the 
last year. CHL screening was indicated if the patient was sexually active and had no prior 
screening or the last screening was over a year ago. Additionally, a provider could order CHL 
screening if clinically indicated based on provider judgment. Such situations may have included, 
but were not limited to, a patient presenting with symptoms in addition to urinary complaints or 
recent change in sexual partner. Fourth, mandatory pre-screening alerts were created in the plan 
portion of the encounter note. The pre-screening alert options included; GC/CHL screening not 
indicated, GC/CHL screening indicated, ordered, GC/CHL screening indicated, patient declined, 
and other. The provider had to choose one of the above options before the patient was 
discharged. Fifth, if indicated for screening, the patient received one of three tests (urine, self-
collected vaginal swab or cervical swab). It is worthy to note that the project site had not used 
self-collected vaginal swabs until this program. A self-collected vaginal swab instruction sheet 
was created and posted in the restrooms. Staff was also educated on how to instruct patients on 
how to use the self-collected vaginal swabs. The final aspect of the program was CHL screening 
education. The provider had the option to choose if screening education information would 
appear on the patient’s discharge paperwork. The screening education information stated, the 
CDC recommends women under age 25 have annual GC/CHL screening.   
Implementation  
The EBP project proposal was submitted through the campus institutional review board 
(IRB) and approval was obtained under exempt status on August 30, 2016. The pre-data 
collected was collected prior to the implementation and included the number of dysuria visits, 
number of CHL screenings ordered, and the number of positive CHL screenings in 2015. 
The EBP project program began on September 1, 2016. The educational presentation was 
held at the site’s staff meeting in August 2016. The staff educated included five providers, three 
nurses, three medical assistants, three receptionists, and one office manager. The supervising 
physician, clinic director and supervising nurse were the three champions and vital to the success 
of this EBP project. Since the champions were multidisciplinary, the Iowa model was selected to 
guide this EBP project because it focuses on interdisciplinary teamwork. The Iowa model also 
provides a helpful guided step-by-step process to implement EBP.18 
Post-data were collected through out the 3-month trial (September 1st to November 30th 
2016). The post-data collected included the number of women under age 25 pre-screened for 
CHL, the amount of women who declined screening, the number of women who were not 
indicated for screening, and the amount women that fell under the option labeled other. Also 
collected was the number of CHL screenings completed during dysuria visits along with the 
number of positive and negative CHL results. The race and specific age of the women pre-
screened and screened for CHL was accounted for as well. Lastly, the amount of women 
educated on CDC guidelines for CHL screening was collected. 
Results 
 To evaluate the EBP project’s success, EMR data were analyzed. There were 110 dysuria 
visits over the implementation period (September 1 to November 30, 2016). Table 1 summarizes 
the amount of CHL pre-screening done pre and post intervention in dysuria visits in a control 
chart. The post-intervention period showed a significant desirable trend in CHL pre-screening 
rates. In the post intervention period, there were no missed opportunities to pre-screen for CHL. 
In other words, of the 110 dysuria visits, 100% received CHL pre-screening. The pre-
intervention or baseline period showed a significantly undesirable trend in CHL pre-screening 
rates. There were 96% missed opportunities to pre-screen and ultimately screen for CHL in the 
baseline period.  
 
Table 1. CHL Pre-Screening Rate in Dysuria Visits  
 
 
Table 2 shows the CHL pre-screening alert breakdown of the 110 dysuria visits in a bar 
chart. The amount of women not indicated for CHL screening was nearly 51%. The amount of 
women indicated for CHL screening was 49%. Approximately 54 % of the women indicated for 
CHL screening declined testing. The other or delayed screening option was nearly 8% of the 
women indicated. The indicated and ordered option accounted for about 30% of the women 
indicated for CHL screening.  
There were 16 CHL screenings/tests ordered from the 110 dysuria visits. This was about 
a 9% increase in CHL screenings/tests ordered from the baseline period. Table 2  also 
summarizes the amount of patients educated on the CDC CHL screening guidelines. Specifically, 
of the 110 dysuria visits, 29% of the women were educated about CHL screening. 
 There were two positive CHL results during the three months of data collected. In 2015, 
in pre-data collected, there were only 3 positive CHL screenings in this patient population. These 
positive screenings also were not associated with dysuria visits. After only a three-month period, 
two positive CHL results were identified, only one result away for the amount of positive CHL 
results for the entire year in 2015 in this specific patient population.  
 
Table 2. CHL Pre-Screening Alert Options & Education for Dysuria Visits  
 
  
The ethnicity of the 110 women pre-screened for CHL were 56% Caucasian, 20% 
Hispanic, 10% multi-racial, 8% Asian, 6% of an unknown race. Of the 16 CHL screenings 
ordered, 56% were from Caucasian females, 19% from multi-racial females, 13% from Asian 
females, 6% from Hispanic females, and 6% from females of an unknown race. Women age 21 
had the highest number of CHL pre-screenings followed by age 20, 22, 19, 18, 23, and 24.  Of 
the 16 CHL screenings ordered, women age 20 accounted for the most CHL screenings followed 
by age 22, 18, 19, 21, 23, and 24.  
Discussion  
Implications for Practice  
There are several implications for practice after implementing this EBP project and 
analyzing the data. Increasing CHL pre-screening was associated with increased CHL screening 
rates. The increased screening may prevent the spread of CHL at the university and in the 
community. By early recognition of CHL in the two positive cases, this could have likely 
prevented PID and infertility related costs for these two patients. Specific parts of the EBP 
program may translate well and be used at other SHCs. The mandatory pre-screening alerts were 
especially useful in increasing CHL screening because they could not be avoided in the 
encounter note. The pre-screening alerts had to be completed before discharge. This EMR 
change was relatively simple and had a significant impact on the amount of CHL screenings 
ordered. This project showed EMR alerts are an effective way to remind staff to screen for CHL 
during dysuria visits. 
It is important to investigate further some aspects of the program. It would be interesting 
to explore why some women declined CHL screening and if they declined, was screening 
education offered. Another aspect to investigate would be if the provider chose the other/delayed 
option of the pre-screening alerts, did this population of women ever receive CHL screening. To 
know the barriers and reasons for declination may ultimately help increase CHL screening at the 
SHC. Also there were three types of screening tests offered (urine, self-collected vaginal swab 
and cervical swab). The numbers of specific type of screening tests were not collected. It may be 
beneficial for the site to collect this data to see what test was used most and if this method was 
cost effective and feasible for the site. It would also be interesting to explore if the provider or 
the patient preferred one method of testing. Finally, for the women that were not indicated for 
screening, it would be interesting to separate the amount of women who were not sexually active 
from the amount of women who received CHL screening within the past year.  
The next steps for the project site would be to implement the mandatory pre-screening 
EMR alerts in other visit templates. These visit templates could include annual physical exams, 
well women exams, vaginitis, and of course visits directly related to sexually transmitted 
infection screening. Also the leadership of SHC could reeducate SHC staff to use the education 
option in the plan section of the encounter note. This could increase the amount of women 
educated on CDC CHL screening guidelines.  
Conclusions 
 The EBP project met the goal to increase CHL pre-screening and screening in women 
under age 25 who presented to the SHC with urinary symptoms. The EBP project outcomes were 
consistent with the evidence to both screen for CHL in this age group and to use specific 
interventions to increase screening. The practice changes made are a sustainable addition to the 
EMR at the SHC especially the mandatory pre-screening alerts. The efforts made by this project 
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